Bayer/Onyx Nexavar Fails Phase III Melanoma Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx is continuing its melanoma program despite sorafenib’s failure to show a progression-free survival benefit in an advanced melanoma study.
You may also be interested in...
Nexavar Long Term Opportunities Are In Breast, Lung Cancer, Onyx CEO Renton Says
A search is underway for a new CEO to take the helm of the drug maker after Renton’s planned retirement next year.
Nexavar Long Term Opportunities Are In Breast, Lung Cancer, Onyx CEO Renton Says
A search is underway for a new CEO to take the helm of the drug maker after Renton’s planned retirement next year.
Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer
Companies will submit sNDA as soon as possible following study halt because of “superior overall survival efficacy.”